Solventum Corporation (NYSE:SOLV) Receives Average Recommendation of “Hold” from Brokerages

Shares of Solventum Corporation (NYSE:SOLV) have been given a consensus recommendation of “Hold” by the thirteen brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $87.00.

SOLV has been the subject of several research reports. Piper Sandler reissued an “overweight” rating on shares of Solventum in a report on Wednesday, December 17th. Zacks Research lowered Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. Wall Street Zen upgraded Solventum from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. BTIG Research raised Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Tuesday, December 2nd. Finally, UBS Group reaffirmed a “neutral” rating on shares of Solventum in a report on Friday, November 21st.

Solventum Stock Down 1.1%

SOLV stock opened at $79.25 on Friday. The stock has a market cap of $13.75 billion, a P/E ratio of 9.13, a PEG ratio of 8.36 and a beta of 0.35. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 1.03. Solventum has a twelve month low of $60.70 and a twelve month high of $88.20. The company’s 50 day moving average is $78.29 and its two-hundred day moving average is $75.01.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 6th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. Solventum had a net margin of 18.13% and a return on equity of 28.01%. The firm had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same period last year, the firm posted $1.64 EPS. The company’s revenue was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Research analysts expect that Solventum will post 6.58 earnings per share for the current fiscal year.

Solventum announced that its Board of Directors has approved a share repurchase plan on Thursday, November 20th that allows the company to repurchase $1.00 billion in shares. This repurchase authorization allows the company to repurchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Solventum

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Allworth Financial LP lifted its position in Solventum by 2.8% during the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after acquiring an additional 129 shares during the period. CIBC Private Wealth Group LLC raised its stake in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Solventum by 0.7% during the second quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,778 shares of the company’s stock worth $1,500,000 after purchasing an additional 140 shares during the period. BOKF NA lifted its holdings in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after purchasing an additional 141 shares during the period. Finally, CHICAGO TRUST Co NA grew its position in Solventum by 3.0% in the 3rd quarter. CHICAGO TRUST Co NA now owns 5,188 shares of the company’s stock valued at $379,000 after buying an additional 150 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.